|
1
|
Maheedhar K, Bhat RA, Malini R, et al:
Diagnosis of ovarian cancer by Raman spectroscopy: a pilot study.
Photomed Laser Surg. 26:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wegdam W, Moerland PD, Meijer D, et al: A
critical assessment of SELDI-TOF-MS for biomarker discovery in
serum and tissue of patients with an ovarian mass. Proteome Sci.
10:452012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tessitore A, Gaggiano A, Cicciarelli G, et
al: Serum biomarkers identification by mass spectrometry in
high-mortality tumors. Int J Proteomics. 2013:1258582013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kristjansdottir B, Levan K, Partheen K,
Carlsohn E and Sundfeldt K: Potential tumor biomarkers identified
in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.
Clin Proteomics. 10:42013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarojini S, Tamir A, Lim H, et al: Early
detection biomarkers for ovarian cancer. J Oncol. 2012:7090492012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kamai T, Tomosugi N, Abe H, Kaji Y, Oyama
T and Yoshida K: Protein profiling of blood samples from patients
with hereditary leiomyomatosis and renal cell cancer by
surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry. Int J Mol Sci. 13:14518–14532. 2012. View Article : Google Scholar
|
|
7
|
Liu C: The application of SELDI-TOF-MS in
clinical diagnosis of cancers. J Biomed Biotechnol.
2011:2458212011.PubMed/NCBI
|
|
8
|
Kelly P, Paulin F, Lamont D, et al:
Pre-treatment plasma proteomic markers associated with survival in
oesophageal cancer. Br J Cancer. 106:955–961. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simsek C, Sonmez O, Keyf AI, et al:
Importance of serum SELDI-TOF-MS analysis in the diagnosis of early
lung cancer. Asian Pac J Cancer Prev. 14:2037–2042. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Opstal-van Winden AW, Krop EJ, Karedal MH,
et al: Searching for early breast cancer biomarkers by serum
protein profiling of pre-diagnostic serum; a nested case-control
study. BMC Cancer. 11:3812011.PubMed/NCBI
|
|
11
|
Gast MC, van Dulken EJ, van Loenen TK, et
al: Detection of breast cancer by surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry tissue and
serum protein profiling. Int J Biol Markers. 24:130–141.
2009.PubMed/NCBI
|
|
12
|
Seibert V, Ebert MP and Buschmann T:
Advances in clinical cancer proteomics: SELDI-TOF-mass spectrometry
and biomarker discovery. Brief Funct Genomic Proteomic. 4:16–26.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giusti I, D’Ascenzo S and Dolo V:
Microvesicles as potential ovarian cancer biomarkers. Biomed Res
Int. 2013:7030482013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wiesner A: Detection of tumor markers with
ProteinChip technology. Curr Pharm Biotechnol. 5:45–67. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mu AK, Lim BK, Hashim OH and Shuib AS:
Identification of O-glycosylated proteins that are
aberrantly excreted in the urine of patients with early stage
ovarian cancer. Int J Mol Sci. 14:7923–7931. 2013.
|
|
16
|
Callesen AK, Mogensen O, Jensen AK, et al:
Reproducibility of mass spectrometry based protein profiles for
diagnosis of ovarian cancer across clinical studies: a systematic
review. J Proteomics. 75:2758–2772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emanuele VA II, Panicker G, Gurbaxani BM,
Lin JM and Unger ER: Sensitive and specific peak detection for
SELDI-TOF mass spectrometry using a wavelet/neural-network based
approach. PLoS One. 7:e481032012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Diao L, Clarke CH, Coombes KR, et al:
Reproducibility of SELDI spectra across time and laboratories.
Cancer Inform. 10:45–64. 2011.PubMed/NCBI
|
|
19
|
Wang J, Zhang X, Ge X, Guo H, Xiong G and
Zhu Y: Proteomic studies of early-stage and advanced ovarian cancer
patients. Gynecol Oncol. 111:111–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Kong B, Qu X, Jia L, Deng B and
Yang Q: Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Gynecol Oncol. 102:61–66. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Z, Bast RC Jr, Yu Y, et al: Three
biomarkers identified from serum proteomic analysis for the
detection of early stage ovarian cancer. Cancer Res. 64:5882–5890.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moshkovskii SA, Serebryakova MV,
Kuteykin-Teplyakov KB, et al: Ovarian cancer marker of 11.7 kDa
detected by proteomics is a serum amyloid A1. Proteomics.
5:3790–3797. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao XL, Li H, Yu XL, et al: Predicting
early intrahepatic recurrence of hepatocellular carcinoma after
microwave ablation using SELDI-TOF proteomic signature. PLoS One.
8:e824482013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qian JY, Mou SH and Liu CB: SELDI-TOF MS
combined with magnetic beads for detecting serum protein biomarkers
and establishment of a boosting decision tree model for diagnosis
of pancreatic cancer. Asian Pac J Cancer Prev. 13:1911–1915. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
NCCN. NCCN Clinical Guidelines in
Oncology: Ovarian Cacer Including Fallopian Tube Cancer and Primary
Peritoneal Cancer (Vesion 1.2014). 2014.
|
|
26
|
Vlasova MA, Moshkovskii SA, Safarova MP,
Makarov OV and Archakov AI: Molecular diagnostics of ovarian cancer
using proteome techniques. Biomed Khim. 51:367–383. 2005.(In
Russian).
|
|
27
|
Huijbers A, Velstra B, Dekker TJ, et al:
Proteomic serum biomarkers and their potential application in
cancer screening programs. Int J Mol Sci. 11:4175–4193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Bock M, de Seny D, Meuwis MA, et al:
Challenges for biomarker discovery in body fluids using
SELDI-TOF-MS. J Biomed Biotechnol. 2010:9060822010.PubMed/NCBI
|
|
29
|
Cadron I, Van Gorp T, Amant F, et al: The
use of laser microdis-section and SELDI-TOF MS in ovarian cancer
tissue to identify protein profiles. Anticancer Res. 29:1039–1045.
2009.PubMed/NCBI
|
|
30
|
Luo J, Qian JH, Yu JK, Zheng S, Xie X and
Lu WG: Discovery of altered protein profiles in epithelial ovarian
carcinogenesis by SELDI mass spectrometry. Eur J Gynaecol Oncol.
29:233–238. 2008.PubMed/NCBI
|
|
31
|
Toss A, De Matteis E, Rossi E, et al:
Ovarian cancer: can proteomics give new insights for therapy and
diagnosis? Int J Mol Sci. 14:8271–8290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sinha A, Ignatchenko V, Ignatchenko A,
Mejia-Guerrero S and Kislinger T: In-depth proteomic analyses of
ovarian cancer cell line exosomes reveals differential enrichment
of functional categories compared to the NCI 60 proteome. Biochem
Biophys Res Commun. 445:694–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
